CareDx, Inc
CDNA has repaired the business and raised FY26 guidance, but at $53.83 the stock already discounts a lot more than the current earnings base, with valuation stretched versus peers and Q2 helped by $15.6M of out-of-period revenue.
CDNA's business is in better shape than it was two years ago, but the stock no longer reflects a turnaround, it reflects a near-complete rehabilitation. The company is guiding FY26 revenue to $490M-$500M and adjusted EBITDA to $66M-$78M, versus FY2025 revenue of $0.4B and operating margin of 13.5%, and Q2 showed real operating leverage with $25M of adjusted EBITDA at an 18.9% margin. Those are strong facts. The problem is price. At $53.83, investors are paying 25.25x P/E and 6.1x sales, both far above peer averages of 5.7x and 2.7x, after the stock doubled versus its 200-day average and nearly matched its 52-week high.
The core mispricing is that the market is extrapolating a clean second-half acceleration when the bridge is not that clean. Q2 revenue of $132M included $15.6M of out-of-period revenue, and management already told investors that this contribution drops to $8M in Q3 and $4M in Q4. That does not mean the business is weak. It means the headline growth rate overstates the normalized run-rate. At the same time, NavDx is strategically important but economically unfinished, with specialty oncology ASP guided at $770 in Q3 and $795 in Q4, well below management's view that it should move to $1,000-$1,100. Investors are currently underwriting that ASP and margin improvement before it is visible.
The short case does not depend on business deterioration. It depends on a stock that has pulled forward too much future success. Three things matter most from here: first, whether transplant testing volumes can keep compounding from 58,000 in Q2 toward the implied 72,600 in Q3 and 76,300 in Q4; second, whether NavDx billing integration actually closes the ASP gap; third, whether management can hold margin while absorbing $5M-$10M of possible integration investment. If those all work, CDNA can justify a higher intrinsic value over time. If one slips, the multiple has room to compress hard.
Conviction stays at Medium, not High, because the operating momentum is real, short interest at 11.82% can continue to squeeze the stock, and the balance sheet is not a problem. But this is the wrong price for a fresh long. The better stance is to avoid paying peak-turnaround valuation for a business that is still proving the quality and durability of its next leg of growth.
NavDx integration goes smoothly, oncology ASP moves toward $1,000-$1,100, and investors underwrite management's 20% long-term EBITDA margin target earlier.
Transplant growth holds, guidance is met, but valuation compresses toward a more balanced blend as integration and revenue quality questions cap upside.
Out-of-period revenue unwinds faster than expected, NavDx ASP stays near $770-$795, and the market rerates CDNA closer to diagnostic peer sales multiples.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 1 buy / 1 hold / 0 sell) — resolve explicitly.
We suffer more often in imagination than in reality.
FY26 is shaping up as a transition from turnaround to scaled earnings, but the market is already paying up for that path. On current numbers, the stock trades at 25.25x P/E despite management still integrating NavDx, carrying Q2 revenue helped by $15.6M of prior-period catch-up, and only beginning to build oncology ASP toward the stated $1,000-$1,100 range from $770 in Q3 guidance. The moat in transplant diagnostics is stronger today because of Medicare surveillance coverage, Epic integration at 17 centers moving toward 30-40, and embedded clinical workflows, but over 3-5 years AI is more likely to be an efficiency tool than a moat creator here, while molecular oncology remains more competitive and reimbursement-sensitive. The secular TAM is still growing, yet at $53.83 investors are paying for a cleaner, broader, and more durable franchise than the company has fully proven.
- FY26 guidance was raised to $490M-$500M revenue and $66M-$78M adjusted EBITDA, implying roughly 30% growth at the $495M midpoint.
- Valuation is rich at 25.25x P/E and 6.1x P/S versus peer averages of 5.7x and 2.7x, while the quant engine base target is $37.98, or -29.5% versus $53.83.
- Q2 revenue grew 52% to $132M, but included $15.6M of out-of-period revenue that steps down to $8M in Q3 and $4M in Q4.
- The business is executing well: Q2 adjusted EBITDA reached $25M at an 18.9% margin, up from 6.6% a year ago, and management now guides FY26 adjusted EBITDA to $66M-$78M.
- Core demand looks real: testing volume rose 17% to 58,000 in Q2, and FY26 volume guidance is 258,000-266,000 tests with Q4 midpoint volume of 76,300, up 5% sequentially from Q3.
- Regulatory and workflow positioning improved: the final Medicare LCD affirms surveillance coverage across kidney, heart, and lung, while Epic connectivity is live at 17 transplant centers and targeted for 30-40 by year-end.
- Balance sheet risk is low, with debt/equity 0.05, $0.0B total debt, and a 4.58 current ratio, giving the company room to absorb integration spending of $5M-$10M.
- Q2 quality was flattered by $15.6M of out-of-period revenue, and that tailwind fades to $8M in Q3 and $4M in Q4, which makes the second-half run-rate less clean than the headline 52% growth suggests.
- The stock has become crowded after a 93.29% move in three months and now sits 102.1% above its 200-day average of $26.63, leaving little room for any stumble.
- Oncology economics are not yet proven: specialty oncology ASP is guided to only $770 in Q3 and $795 in Q4, well below management's view that it should move to $1,000-$1,100, and integration could require $5M-$10M of extra investment.
- Valuation leaves little margin of safety, with 25.25x P/E against a peer average of 5.7x, and the quant framework's methods span only $22.20 to $62.87, signaling unusually wide outcome dispersion.
| Metric | Value | Context |
|---|---|---|
| Current price | $53.83 | Reference price for target and scenario analysis |
| Quant price target | $37.98 | -29.5% vs current, Low confidence, basis: earnings_growth_blend |
| FY2025 revenue | $0.4B | +16.6% YoY |
| FY2025 EPS | $-0.40 | -142.1% YoY |
| FY2025 operating margin | 13.5% | Up from 12.2% in prior FY |
| FY2025 net margin | 17.0% | Boosted by divestiture-related accounting and other non-core items |
| Valuation | 25.25x P/E, 6.1x P/S, 6.56x P/B | Above peer averages of 5.7x P/E and 2.7x P/S |
| FY26 guidance | $490M-$500M revenue, $66M-$78M adjusted EBITDA | Raised on 2026 Q2 call |
| Q2 2026 | $132M revenue, $25M adjusted EBITDA, 18.9% EBITDA margin | Revenue +52% YoY, included $15.6M out-of-period revenue |
| Balance sheet | Debt/Equity 0.05, Current ratio 4.58, Total debt $0.0B | Low financial risk |
| Price action | +93.29% in 3M, -2.4% vs 52-week high, +102.1% vs 200-day average | Momentum strong, setup crowded |
| Short interest | 11.82% | 5,828,536 shares, 5.7 days-to-cover |
The biggest risk to the SELL is that FY26 guidance proves conservative and NavDx scales faster than expected, because revenue of $490M-$500M and long-term EBITDA margin ambition of 20% could support materially higher earnings power than the current base-case model assumes.
The next catalyst is the November 3, 2026 earnings report, with focus on whether Q3 can absorb the step-down from $15.6M to $8M of out-of-period revenue while sustaining EBITDA momentum and showing oncology ASP progress from $770 toward the $1,000-$1,100 target.
Ownership is tight, with the top three institutions holding 89.7% and insiders at 3.8%, which can amplify moves when fundamentals change. Short interest is meaningful at 11.82%, or 5,828,536 shares and 5.7 days to cover, which helps explain the sharp rally and leaves room for squeezes around earnings. Options positioning is supportive near term, with a positive GEX regime and zero-gamma at $49.32, below spot, but that is a trading tailwind, not a valuation support.
Core transplant surveillance business, Q2 testing services revenue grew 61% and testing volume rose 17% to 58,000.
Integrated from July 1; growth driver, but near-term ASP is only $770 in Q3 and $795 in Q4 pending billing integration.
Sold for $172M consideration, simplifying the model and increasing mix toward higher-margin testing revenue.
Medicare LCD and U.S. transplant center workflow integration are the main current demand drivers.
CareDx posted a strong Q2 and raised FY26 revenue and EBITDA guidance with NavDx adding 2H growth.
Management's execution record has improved meaningfully versus the 2024 Q3 setup. Back then, CDNA guided FY24 revenue to $327M-$331M and adjusted EBITDA to $18M-$22M, after reporting Q3 revenue of $82.9M and EBITDA margin of 8.3%. By 2026 Q2, the company had raised FY26 guidance to $490M-$500M revenue and $66M-$78M adjusted EBITDA, while Q2 delivered $132M revenue and $25M adjusted EBITDA at an 18.9% margin. The strategy also progressed on the specific milestones management highlighted: surveillance demand did recover, Medicare coverage broadened, Epic integration is now live at 17 centers with 30-40 targeted by year-end, and AlloHeme remains on track for year-end CLIA readiness with a planned 2027 launch. The earnings track record supports credibility, with beats in 7 of the last 8 reported quarters, including +503.0%, +209.1%, and +59.4% EPS surprises in the last three quarters, though the 2025-08-06 miss and the reliance on $15.6M out-of-period revenue in Q2 argue for some caution.
We are raising 2026 revenue guidance to $490 million to $500 million, representing a 30% increase year-over-year at the $495 million midpoint of the range and adjusted EBITDA from $66 million to $78 million or 15% of revenue at the $72 million midpoint of the range.
The midpoint of our guidance assumes Q3 testing volume of 72,600 tests with transplant volumes of 58,000 and specialty oncology volume of 14,600. For Q4, the midpoint of our guidance assumes testing volume increase sequentially 5% to 76,300 tests with transplant volumes of 60,000 and specialty oncology volumes of 16,300 tests.
Total revenue increased 52% to $132 million. Adjusted EBITDA increased $19 million to $25 million or 19% of revenue.
I do believe that number should move up to $1,000 to $1,100. They get $1,800 from Medicare.
We do believe we should be running at 20% EBITDA margins long-term. We do believe that.
CDNA's moat sits in transplant diagnostics workflow, not in commodity lab capacity. Medicare surveillance coverage across kidney, heart, and lung, clinical data sets, and Epic connectivity live at 17 transplant centers create switching friction and help lock in recurring surveillance testing. Durability looks solid in transplant over the next few years, but less proven in specialty oncology where reimbursement, ASP, and competitor intensity are still forming.
Capital allocation has become more disciplined. The company divested lab products for $172M, recognized a $113M GAAP operating gain, and is concentrating resources on higher-margin testing and oncology expansion rather than supporting a lower-quality product mix. Shareholder returns are minimal today, with $0.0B buybacks, $0.0B dividends, and $0.0B stated capex and FCF in the supplied data, so the case depends on reinvestment and margin expansion rather than capital return.
CDNA is a better business than it was, but not a better stock at $53.83. Rated SELL, Medium conviction, because the stock price now assumes successful NavDx integration, ASP improvement, and sustained transplant growth while leaving little room for any slowdown after a 93.29% three-month run. The balance sheet is strong and management is executing, so this is not a broken-company short. It is a valuation and setup call. The rating would change if the stock retraced materially toward the high $30s or if CDNA proves a durable earnings base with oncology ASP moving toward $1,000-$1,100 without sacrificing margin.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. CDNA rates a SELL at Medium conviction. The operating story has improved materially, with FY26 revenue guided to $490M-$500M and adjusted EBITDA to $66M-$78M, but the stock is trading 2.4% below its 52-week high after a 93.29% three-month run and at 25.25x P/E and 6.1x sales, both well above peer averages of 5.7x and 2.7x. The setup now depends on flawless integration of NavDx, sustained transplant test growth, and ASP uplift in oncology, which is too much to pay for given low confidence valuation support and a base-case target of $37.98.
Investment Thesis
CDNA's business is in better shape than it was two years ago, but the stock no longer reflects a turnaround, it reflects a near-complete rehabilitation. The company is guiding FY26 revenue to $490M-$500M and adjusted EBITDA to $66M-$78M, versus FY2025 revenue of $0.4B and operating margin of 13.5%, and Q2 showed real operating leverage with $25M of adjusted EBITDA at an 18.9% margin. Those are strong facts. The problem is price. At $53.83, investors are paying 25.25x P/E and 6.1x sales, both far above peer averages of 5.7x and 2.7x, after the stock doubled versus its 200-day average and nearly matched its 52-week high.
The core mispricing is that the market is extrapolating a clean second-half acceleration when the bridge is not that clean. Q2 revenue of $132M included $15.6M of out-of-period revenue, and management already told investors that this contribution drops to $8M in Q3 and $4M in Q4. That does not mean the business is weak. It means the headline growth rate overstates the normalized run-rate. At the same time, NavDx is strategically important but economically unfinished, with specialty oncology ASP guided at $770 in Q3 and $795 in Q4, well below management's view that it should move to $1,000-$1,100. Investors are currently underwriting that ASP and margin improvement before it is visible.
The short case does not depend on business deterioration. It depends on a stock that has pulled forward too much future success. Three things matter most from here: first, whether transplant testing volumes can keep compounding from 58,000 in Q2 toward the implied 72,600 in Q3 and 76,300 in Q4; second, whether NavDx billing integration actually closes the ASP gap; third, whether management can hold margin while absorbing $5M-$10M of possible integration investment. If those all work, CDNA can justify a higher intrinsic value over time. If one slips, the multiple has room to compress hard.
Conviction stays at Medium, not High, because the operating momentum is real, short interest at 11.82% can continue to squeeze the stock, and the balance sheet is not a problem. But this is the wrong price for a fresh long. The better stance is to avoid paying peak-turnaround valuation for a business that is still proving the quality and durability of its next leg of growth.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $53.83 | Reference price for target and scenario analysis |
| Quant price target | $37.98 | -29.5% vs current, Low confidence, basis: earnings_growth_blend |
| FY2025 revenue | $0.4B | +16.6% YoY |
| FY2025 EPS | $-0.40 | -142.1% YoY |
| FY2025 operating margin | 13.5% | Up from 12.2% in prior FY |
| FY2025 net margin | 17.0% | Boosted by divestiture-related accounting and other non-core items |
| Valuation | 25.25x P/E, 6.1x P/S, 6.56x P/B | Above peer averages of 5.7x P/E and 2.7x P/S |
| FY26 guidance | $490M-$500M revenue, $66M-$78M adjusted EBITDA | Raised on 2026 Q2 call |
| Q2 2026 | $132M revenue, $25M adjusted EBITDA, 18.9% EBITDA margin | Revenue +52% YoY, included $15.6M out-of-period revenue |
| Balance sheet | Debt/Equity 0.05, Current ratio 4.58, Total debt $0.0B | Low financial risk |
| Price action | +93.29% in 3M, -2.4% vs 52-week high, +102.1% vs 200-day average | Momentum strong, setup crowded |
| Short interest | 11.82% | 5,828,536 shares, 5.7 days-to-cover |
Financial Strength
The balance sheet is not the issue here. CDNA carries $0.0B of total debt, 0.05 debt-to-equity, and a 4.58 current ratio, which supports the low financial risk score and gives management room to fund oncology integration and product launches. Margin direction is also improving, with FY2025 operating margin at 13.5% and Q2 adjusted EBITDA margin reaching 18.9%, helped by higher volume, better gross margin, and stronger collections. The only caution is cash conversion quality in the reported numbers: the supplied annual FCF reads $0.0B, while the call cites $31M cash from operations in Q2, so investors should focus on normalized post-integration cash generation rather than one-quarter strength or GAAP gains tied to the lab products divestiture.
Competitive Position
CDNA's moat sits in transplant diagnostics workflow, not in commodity lab capacity. Medicare surveillance coverage across kidney, heart, and lung, clinical data sets, and Epic connectivity live at 17 transplant centers create switching friction and help lock in recurring surveillance testing. Durability looks solid in transplant over the next few years, but less proven in specialty oncology where reimbursement, ASP, and competitor intensity are still forming.
Management & Guidance
Management's current guide is assertive but not reckless. The company now expects FY26 revenue of $490M-$500M, adjusted EBITDA of $66M-$78M, testing volume of 258,000-266,000, non-GAAP gross margin of 71%-73%, and non-GAAP operating expenses of $293M-$297M. The credibility is better than average because the company has beaten EPS in 7 of the last 8 quarters and specifically raised guidance after a Q2 that delivered $25M of adjusted EBITDA. Still, investors should haircut the headline because Q2 contained $15.6M of out-of-period revenue, and management itself flagged $5M-$10M of potential integration investment and subscale oncology ASPs of $770 in Q3 and $795 in Q4 before billing normalization.
Segment Analysis
- Testing Services (Majority of revenue, exact FY25 split not disclosed in provided data): Core transplant surveillance business, Q2 testing services revenue grew 61% and testing volume rose 17% to 58,000.
- Specialty Oncology (NavDx) ($24M of 2H26 revenue in guidance): Integrated from July 1; growth driver, but near-term ASP is only $770 in Q3 and $795 in Q4 pending billing integration.
- Lab Products (Divested on June 30, 2026): Sold for $172M consideration, simplifying the model and increasing mix toward higher-margin testing revenue.
- Geography (Primarily U.S., exact split not disclosed in provided data): Medicare LCD and U.S. transplant center workflow integration are the main current demand drivers.
Capital Allocation
Capital allocation has become more disciplined. The company divested lab products for $172M, recognized a $113M GAAP operating gain, and is concentrating resources on higher-margin testing and oncology expansion rather than supporting a lower-quality product mix. Shareholder returns are minimal today, with $0.0B buybacks, $0.0B dividends, and $0.0B stated capex and FCF in the supplied data, so the case depends on reinvestment and margin expansion rather than capital return.
Management Execution & Track Record
Management's execution record has improved meaningfully versus the 2024 Q3 setup. Back then, CDNA guided FY24 revenue to $327M-$331M and adjusted EBITDA to $18M-$22M, after reporting Q3 revenue of $82.9M and EBITDA margin of 8.3%. By 2026 Q2, the company had raised FY26 guidance to $490M-$500M revenue and $66M-$78M adjusted EBITDA, while Q2 delivered $132M revenue and $25M adjusted EBITDA at an 18.9% margin. The strategy also progressed on the specific milestones management highlighted: surveillance demand did recover, Medicare coverage broadened, Epic integration is now live at 17 centers with 30-40 targeted by year-end, and AlloHeme remains on track for year-end CLIA readiness with a planned 2027 launch. The earnings track record supports credibility, with beats in 7 of the last 8 reported quarters, including +503.0%, +209.1%, and +59.4% EPS surprises in the last three quarters, though the 2025-08-06 miss and the reliance on $15.6M out-of-period revenue in Q2 argue for some caution.
Positioning & Flows
Ownership is tight, with the top three institutions holding 89.7% and insiders at 3.8%, which can amplify moves when fundamentals change. Short interest is meaningful at 11.82%, or 5,828,536 shares and 5.7 days to cover, which helps explain the sharp rally and leaves room for squeezes around earnings. Options positioning is supportive near term, with a positive GEX regime and zero-gamma at $49.32, below spot, but that is a trading tailwind, not a valuation support.
Bull Case
- The business is executing well: Q2 adjusted EBITDA reached $25M at an 18.9% margin, up from 6.6% a year ago, and management now guides FY26 adjusted EBITDA to $66M-$78M.
- Core demand looks real: testing volume rose 17% to 58,000 in Q2, and FY26 volume guidance is 258,000-266,000 tests with Q4 midpoint volume of 76,300, up 5% sequentially from Q3.
- Regulatory and workflow positioning improved: the final Medicare LCD affirms surveillance coverage across kidney, heart, and lung, while Epic connectivity is live at 17 transplant centers and targeted for 30-40 by year-end.
- Balance sheet risk is low, with debt/equity 0.05, $0.0B total debt, and a 4.58 current ratio, giving the company room to absorb integration spending of $5M-$10M.
Bear Case
- Q2 quality was flattered by $15.6M of out-of-period revenue, and that tailwind fades to $8M in Q3 and $4M in Q4, which makes the second-half run-rate less clean than the headline 52% growth suggests.
- The stock has become crowded after a 93.29% move in three months and now sits 102.1% above its 200-day average of $26.63, leaving little room for any stumble.
- Oncology economics are not yet proven: specialty oncology ASP is guided to only $770 in Q3 and $795 in Q4, well below management's view that it should move to $1,000-$1,100, and integration could require $5M-$10M of extra investment.
- Valuation leaves little margin of safety, with 25.25x P/E against a peer average of 5.7x, and the quant framework's methods span only $22.20 to $62.87, signaling unusually wide outcome dispersion.
Valuation & Price Target
Engine price target $37.98 (-29.5% vs current), Low confidence.
- P/E Multiple: $25.78 (13% weight)
- PEG (growth-adjusted): $36.77 (20% weight)
- P/S Multiple: $22.2 (20% weight)
- Quality-adjusted: $62.87 (20% weight)
The quant baseline is SELL (Low conviction) with a $37.98 target, and that remains the right direction even after acknowledging better operations. The reason not to override it to BUY is simple: the stock at $53.83 is priced above the engine's base value by 29.5%, trades at 25.25x P/E versus 5.7x peer average with 3.2x wide peer dispersion, and just rallied 93.29% in three months to sit 2.4% below its 52-week high. The bullish rebuttal is real, FY26 revenue is guided to $490M-$500M, EBITDA to $66M-$78M, and the balance sheet is clean with $0.0B debt, but the valuation already capitalizes much of that repair while Q2 included $15.6M of catch-up revenue and oncology ASP still starts from $770-$795. Sell-side consensus is a low-signal Strong Buy from only 2 firms, which does not outweigh the valuation and setup concerns.
Risk Assessment
Risk score 34/100 (Low). The biggest risk to the SELL is that FY26 guidance proves conservative and NavDx scales faster than expected, because revenue of $490M-$500M and long-term EBITDA margin ambition of 20% could support materially higher earnings power than the current base-case model assumes.
The Bottom Line
CDNA is a better business than it was, but not a better stock at $53.83. Rated SELL, Medium conviction, because the stock price now assumes successful NavDx integration, ASP improvement, and sustained transplant growth while leaving little room for any slowdown after a 93.29% three-month run. The balance sheet is strong and management is executing, so this is not a broken-company short. It is a valuation and setup call. The rating would change if the stock retraced materially toward the high $30s or if CDNA proves a durable earnings base with oncology ASP moving toward $1,000-$1,100 without sacrificing margin.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr